公开(公告)号：US10576082B2

公开(公告)日：2020-03-03

申请号：US16329070

申请日：2017-09-03

Applicant: Academia Sinica

Inventor： Yung-Feng Liao ,  Bo-Jeng Wang

IPC: A61K48/00 ,  C07H21/02 ,  C07H21/04 ,  A61K31/517 ,  A61P25/28 ,  C12N15/113 ,  A61P25/00

Abstract: Use of an ErbB2 inhibitor for promoting ErbB2-regulated autophagic degradation or clearance of APP-C99 and APP intracellular domain (AICD) and/or alleviating production of Abeta 40 and Abeta 42 in a subject in need thereof is disclosed. Use of an ErbB2 inhibitor for rescuing ErbB2-mediated inhibition of autophagic flux in a subject in need thereof is also disclosed. Use of an ErbB2 inhibitor for enhancing spatial learning and memory, and/or for cognitive improvement, in a subject with ErbB2-associated Alzheimer's disease is further disclosed. Also disclosed is use of an ErbB2 inhibitor for reducing intracellular levels of C99 and AICD without affecting extracellular domain-truncated Notch and Notch intracellular domain in a subject in need thereof.

公开(公告)号：US20200046826A1

公开(公告)日：2020-02-13

申请号：US16431099

申请日：2019-06-04

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Che Ma ,  Cheng-Chi Wang ,  Juine-Ruey Chen

IPC: A61K39/145 ,  A61K39/12 ,  C07K16/10 ,  C12N7/00

Abstract: Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection against viruses, even across strains. Pharmaceutical compositions comprising monoglycosylated hemagglutinin polypeptides and vaccines generated therefrom and methods of their use for prophylaxis or treatment of viral infections are disclosed. Methods and compositions are disclosed for influenza virus HA, NA and M2, RSV proteins F, G and SH, Dengue virus glycoproteins M or E, hepatitis C virus glycoprotein E1 or E2 and HIV glycoproteins gp120 and gp41.

公开(公告)号：US10558926B2

公开(公告)日：2020-02-11

申请号：US14947002

申请日：2015-11-20

Applicant: Academia Sinica

Inventor： Wen-lian Hsu

IPC: G06N5/04 ,  G06F17/27 ,  G06N5/02

Abstract: An apparatus for extracting selected information from a set of symbols includes said alignment module is configured to retrieve test patterns from a symbol input, and to attempt alignment of test patterns with a canonical pattern. Successful alignment between a particular test pattern and said canonical pattern indicates of existence of information of interest in a particular candidate pattern. Upon detection of a successful alignment, the alignment module passes information concerning the test pattern to a user. Additionally, in response to detecting an unsuccessful attempt to align the first test pattern and the canonical pattern, said alignment module passes, to said user, information concerning the first test pattern.

公开(公告)号：US10472411B2

公开(公告)日：2019-11-12

申请号：US16409994

申请日：2019-05-13

Applicant: Academia Sinica

Inventor： An-Suei Yang ,  Hong-Sen Chen ,  Ing-Chien Chen ,  Chao-Ping Tung ,  Shin-Chen Hou ,  Chung-Ming Yu ,  Chi-Kai Yang ,  Yi-Kai Chiu

IPC: C07K16/00 ,  C12N15/10 ,  C07K16/28 ,  C07K16/18 ,  C07K16/22 ,  C07K16/24 ,  C07K16/32 ,  C07K16/10

Abstract: Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.

公开(公告)号：US10434132B2

公开(公告)日：2019-10-08

申请号：US16172428

申请日：2018-10-26

Applicant: ACADEMIA SINICA

Inventor： Lie-Fen Shyur ,  Jia-Hua Feng ,  Maria Karmella Apaya

IPC: A61K36/00 ,  A61K36/88 ,  A61K31/25 ,  A61K36/28 ,  A61K8/9794 ,  A61Q19/02 ,  A61P1/16 ,  A61P31/04

Abstract: The present invention is related to a galactolipids-enriched plant extract, prepared by extracting a plant sample selected from a group consisting of: Gynura divaricata subsp. formosana (Asteraceae) (GD), Murdannia bracteata (C. B. Clarke) J. K. Morton ex D. Y. Hong (Commelinaceae) (MB), and Crassocephalum rabens S. Moore (Asteraceae) (CR) with a series of solvents. A pharmaceutical, nutritional, or healthcare composition for protecting or treating acute fulminant hepatitis, for protecting or treating sepsis or related indication thereof, and a composition for skin whitening are also provided herein. These compositions all comprise effective amounts of the galactolipids-enriched plant extracts or purified compounds thereof as bioactive ingredients.

公开(公告)号：US10407720B2

公开(公告)日：2019-09-10

申请号：US15037322

申请日：2014-12-14

Applicant: ACADEMIA SINICA

Inventor： Kuo Ping Chiu ,  Yu-Shin Nai

IPC: C12Q1/686 ,  G16B30/00 ,  C12Q1/6869 ,  C12Q1/6886 ,  C12Q1/6855 ,  G16B35/00 ,  G16C20/60

Abstract: An adaptor for use in amplifying all linear, double-stranded nucleic acid molecules of unknown sequences in a sample is disclosed. The adaptor consists of: (1) the first oligonucleotide (P-oligo) with a phosphate at the 5′ end and without an additional thymine nucleotide at the 3′ end; and (2) the second oligonucleotide (T˜oligo) with an extra 3′-T and without a 5′-phosphate. The P-oligo and T-oligo are complementary to each other except at the 3′-T (thymine) in the T-oligo. The adaptor is ligated to nucleic acids of unknown sequences which have an extra A in the 3′ end (3′˜A overhang) to form adaptor-ligated target nucleic acids. The T-oligo is then employed as a single primer for T-oligo-primed polymerase chain reaction (TOP-PCR) and amplifies the nucleic acids of unknown sequences in full-length.

公开(公告)号：US20190209565A1

公开(公告)日：2019-07-11

申请号：US16329070

申请日：2017-09-03

Applicant: Academia Sinica

Inventor： Yung-Feng LIAO ,  Bo-Jeng WANG

IPC: A61K31/517 ,  C12N15/113 ,  A61P25/28

CPC classification number: A61K31/517 ,  A61P25/00 ,  A61P25/28 ,  C12N15/113 ,  C12N15/1138 ,  C12N2310/122 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2740/16043

Abstract: Use of an ErbB2 inhibitor for promoting ErbB2-regulated autophagic degradation or clearance of APP-C99 and APP intracellular domain (AICD) and/or alleviating production of Abeta 40 and Abeta 42 in a subject in need thereof is disclosed. Use of an ErbB2 inhibitor for rescuing ErbB2-mediated inhibition of autophagic flux in a subject in need thereof is also disclosed. Use of an ErbB2 inhibitor for enhancing spatial learning and memory, and/or for cognitive improvement, in a subject with ErbB2-associated Alzheimer's disease is further disclosed. Also disclosed is use of an ErbB2 inhibitor for reducing intracellular levels of C99 and AICD without affecting extracellular domain-truncated Notch and Notch intracellular domain in a subject in need thereof.

公开(公告)号：US10336816B2

公开(公告)日：2019-07-02

申请号：US15547523

申请日：2016-02-23

Applicant: Academia Sinica

Inventor： An-Suei Yang ,  Hong-Sen Chen ,  Ing-Chien Chen ,  Chao-Ping Tung ,  Shin-Chen Hou ,  Chung-Ming Yu ,  Chi-Kai Yang ,  Yi-Kai Chiu

IPC: C07K16/00 ,  C07K16/22 ,  C07K16/32 ,  C12N15/10 ,  C07K16/10 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28

Abstract: Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.

公开(公告)号：US20190119713A1

公开(公告)日：2019-04-25

申请号：US16018400

申请日：2018-06-26

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Chung-Yi WU ,  Che MA

IPC: C12P19/14 ,  C07K16/28 ,  A61K45/06 ,  C07K16/32 ,  A61K39/395 ,  C12N9/24 ,  C07K16/10 ,  C07K16/00 ,  A61K39/42 ,  C07K16/30 ,  C07K16/18 ,  C07K16/24

Abstract: The present disclosure relates to glycoproteins, particularly monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-glycan having the structure of Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2. The glycoengineered Fc region binds FcγRIIA or FcγRIIIA with a greater affinity, relative to comparable monoclonal antibodies comprising the wild-type Fc region. The monoclonal antibodies of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, autoimmune, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

公开(公告)号：US10214564B2

公开(公告)日：2019-02-26

申请号：US14766359

申请日：2014-02-05

Applicant: Academia Sinica

Inventor： Chiaho Shih ,  Heng-Li Chen ,  Pei-Yi Su

IPC: C07K14/005 ,  C12N7/00 ,  A61K39/29 ,  A61K39/12 ,  A61K38/00

Abstract: A pharmaceutical composition for use in killing and/or inhibiting the growth and/or proliferation of a microorganism in a subject in need thereof, or for treating a subject afflicted with a microbial infection is disclosed. The composition comprises: (a) an effective amount of an isolated peptide, wherein the peptide comprises the arginine-rich carboxy-terminal region of hepatitis B virus core protein (HBc) and exhibits an antimicrobial activity; and (b) a pharmaceutically acceptable carrier. The peptide exhibits an activity against Gram-negative bacteria, Gram-positive bacteria, and/or fungi.